Advanced search

Online first
Guidelines / Expert consensus
Published online: 2025-03-12

open access

View PDF Download PDF file
Page views 86
Article views/downloads 62
Get Citation

Connect on Social Media

Connect on Social Media

Post-transplant lymphoproliferative diseases: Polish Lymphoma Research Group 2025 recommendations for diagnosis and treatment

Bartosz Puła1, Joanna Drozd-Sokołowska2, Anna Czyż3, Sebastian Giebel4, Ewa Lech-Marańda5, Lidia Gil6, Tomasz Wróbel3, Jan Styczyński7, Jan Maciej Zaucha8
DOI: 10.5603/ahp.103957

Abstract

Post-transplant lymphoproliferative disorders (PTLD) are a category of iatrogenic lymphoproliferative syndromes associated with immunodeficiencies. PTLD is defined as any lymphoproliferation (except lymphoproliferation from small B lymphocytes) occurring after organ transplantation or allogeneic hematopoietic stem cell transplantation, regardless of the time elapsed since transplantation. The diagnosis of PTLD is based on histopathological examination of the lymph node or suspicious lesion. The main treatment goal is eradication of PTLD, with a concomitant maintenance of graft function. This article presents the latest diagnosis and treatment recommendations of the Polish Lymphoma Research Group.

Keywords: treatmentlymphomatransplantationimmunochemotherapyimmunosuppressionEpstein–Barr virus

Article available in PDF format

View PDF Download PDF file

References

  1. Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, et al. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023; 482(1): 227–244.
    CrossRefPubMed
  2. Alaggio R, Amador C, Anagnostopoulos I, et al. International Agency for Research on Cancer/World Health Organization. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720–1748.
    CrossRefPubMed
  3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375–2390.
    CrossRefPubMed
  4. King RL, Khurana A, Mwangi R, et al. Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. Hemasphere. 2021; 5(10): e640.
    CrossRefPubMed
  5. Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89(7): 1221–1227.
    CrossRefPubMed
  6. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999; 94(7): 2208–2216.
    PubMed
  7. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation Assessment of the Risk of Lymphoproliferative Disorder. Clinical Infectious Diseases. 1995; 20(5): 1346–1353.
    CrossRef
  8. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993; 342(8886-8887): 1514–1516.
    CrossRefPubMed
  9. Cockfield SM, Preiksaitis JK, Jewell LD, et al. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation. 1993; 56(1): 88–96.
    CrossRefPubMed
  10. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001; 3(2): 70–78.
    CrossRefPubMed
  11. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation. 2005; 80(2): 193–197.
    CrossRefPubMed
  12. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 1991; 10(6): 86–87.
  13. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990; 323(25): 1723–1728.
    CrossRefPubMed
  14. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med. 1996; 154(6 Pt 1): 1712–1717.
    CrossRefPubMed
  15. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest. 1999; 116(5): 1273–1277.
    CrossRefPubMed
  16. Smith JM, Rudser K, Gillen D, et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation. 2006; 81(2): 175–180.
    CrossRefPubMed
  17. Styczynski J, Gil L, Tridello G, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013; 57(6): 794–802.
    CrossRefPubMed
  18. Lucas KG, Small TN, Heller G, et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood. 1996; 87(6): 2594–2603.
    PubMed
  19. Meij P, van Esser JWJ, Niesters HGM, et al. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003; 101(11): 4290–4297.
    CrossRefPubMed
  20. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010; 10(3): 547–557.
    CrossRefPubMed
  21. Vincenti F, Larsen C, Durrbach A, et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353(8): 770–781.
    CrossRefPubMed
  22. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007; 7(7): 1770–1777.
    CrossRefPubMed
  23. Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006; 81(9): 1227–1233.
    CrossRefPubMed
  24. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009; 113(20): 4992–5001.
    CrossRefPubMed
  25. Funch DP, Ko HH, Travasso J, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation. 2005; 80(9): 1174–1180.
    CrossRefPubMed
  26. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007; 7(11): 2619–2625.
    CrossRefPubMed
  27. McDonald RA, Smith JM, Ho M, et al. CCTPT Study Group. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008; 8(5): 984–989.
    CrossRefPubMed
  28. Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation. 2003; 75(6): 851–856.
    CrossRefPubMed
  29. Zangwill SD, Hsu DT, Kichuk MR, et al. Jr., Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 1998; 17(12): 1161–6.
  30. Caillard S, Cellot E, Dantal J, et al. French PTLD Registry. A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders. Clin J Am Soc Nephrol. 2017; 12(10): 1663–1670.
    CrossRefPubMed
  31. Petrara MR, Giunco S, Serraino D, et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett. 2015; 369(1): 37–44.
    CrossRefPubMed
  32. Murata T, Sugimoto A, Inagaki T, et al. Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation. Viruses. 2021; 13(12).
    CrossRefPubMed
  33. Nagle SJ, Reshef R, Tsai DE. Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation. Clin Chest Med. 2017; 38(4): 771–783.
    CrossRefPubMed
  34. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995; 80(3): 389–399.
    CrossRefPubMed
  35. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1997; 94(4): 1447–1452.
    CrossRefPubMed
  36. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998; 338(20): 1413–1421.
    CrossRefPubMed
  37. Kaiser C, Laux G, Eick D, et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol. 1999; 73(5): 4481–4484.
    CrossRefPubMed
  38. Szymula A, Palermo RD, Bayoumy A, et al. Correction: Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome. PLoS Pathog. 2019; 15(2): e1007403.
    CrossRefPubMed
  39. Zhang B, Kracker S, Yasuda T, et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell. 2012; 148(4): 739–751.
    CrossRefPubMed
  40. Parker A, Bowles K, Bradley JA, et al. Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010; 149(5): 675–692.
    CrossRefPubMed
  41. Styczynski J, van der Velden W, Fox CP, et al. Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7): 803–811.
    CrossRefPubMed
  42. Gupta D, Mendonca S, Chakraborty S, et al. Post Transplant Lymphoproliferative Disorder. Indian J Hematol Blood Transfus. 2020; 36(2): 229–237.
    CrossRefPubMed
  43. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: IARC; 2017. https://www.iarc.who.int/news-events/who-classification-of-tumours-of-haematopoietic-and-lymphoid-tissues-2/.
  44. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999; 68(10): 1517–1525.
    CrossRefPubMed
  45. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant. 2002; 17 Suppl 4: 31–3, 35.
    CrossRefPubMed
  46. Caillard S, Agodoa LY, Bohen EM, et al. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation. 2006; 81(6): 888–895.
    CrossRefPubMed
  47. Wang TF, Klein JL, Woodard PK, et al. Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. J Clin Oncol. 2012; 30(27): e278–e282.
    CrossRefPubMed
  48. Mbulaiteye SM, Clarke CA, Morton LM, et al. Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am J Hematol. 2013; 88(4): 245–250.
    CrossRefPubMed
  49. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol. 1995; 13(4): 961–968.
    CrossRefPubMed
  50. Draoua HY, Tsao L, Mancini DM, et al. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol. 2004; 127(4): 429–432.
    CrossRefPubMed
  51. Rajakariar R, Bhattacharyya M, Norton A, et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant. 2004; 4(9): 1534–1538.
    CrossRefPubMed
  52. Barba T, Bachy E, Maarek A, et al. Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. Transplantation. 2021; 105(8): 1858–1868.
    CrossRefPubMed
  53. Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant. 2008; 8(5): 1016–1024.
    CrossRefPubMed
  54. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001; 72(6): 1012–1019.
    CrossRefPubMed
  55. Baldanti F, Rognoni V, Cascina A, et al. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virol J. 2011; 8: 421.
    CrossRefPubMed
  56. Shimizu H, Saitoh T, Koya H, et al. Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol. 2011; 94(5): 495–498.
    CrossRefPubMed
  57. Sirvent-Von Bueltzingsloewen A, Morand P, Buisson M, et al. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplant. 2002; 29(1): 21–28.
    CrossRefPubMed
  58. van Esser JW, Niesters HG, Thijsen SF, et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol. 2001; 113(3): 814–821.
    CrossRefPubMed
  59. Bakker NA, Pruim J, de Graaf W, et al. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant. 2006; 6(8): 1984–1985.
    CrossRefPubMed
  60. Dierickx D, Tousseyn T, Requilé A, et al. The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica. 2013; 98(5): 771–775.
    CrossRefPubMed
  61. Kim DH, Kim SJ, Kim DH, et al. Diagnostic performances of F-18 FDG PET or PET/CT for detection of post-transplant lymphoproliferative disorder: a systematic review and meta-analysis. Nucl Med Commun. 2020; 41(6): 533–539.
    CrossRefPubMed
  62. Ballova V, Muoio B, Albano D, et al. Diagnostic Performance of F-FDG PET or PET/CT for Detection of Post-Transplant Lymphoproliferative Disorder: A Systematic Review and a Bivariate Meta-Analysis. Diagnostics (Basel). 2020; 10(2).
    CrossRefPubMed
  63. Montes de Jesus FM, Kwee TC, Nijland M, et al. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018; 132: 27–38.
    CrossRefPubMed
  64. Montes de Jesus FM, Kwee TC, Kahle XU, et al. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield. Eur J Nucl Med Mol Imaging. 2020; 47(3): 529–536.
    CrossRefPubMed
  65. Gheysens O, Thielemans S, Morscio J, et al. Detection of bone marrow involvement in newly diagnosed post-transplant lymphoproliferative disorder: (18)F-fluorodeoxyglucose positron emission tomography/computed tomography versus bone marrow biopsy. Leuk Lymphoma. 2016; 57(10): 2382–2388.
    CrossRefPubMed
  66. Cavaliere R, Petroni G, Lopes MB, et al. International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010; 116(4): 863–870.
    CrossRefPubMed
  67. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32(27): 3048–3058.
    CrossRefPubMed
  68. Cheson BD, Fisher RI, Barrington SF, et al. Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059–3068.
    CrossRefPubMed
  69. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12): e538–e548.
    CrossRefPubMed
  70. Szulgo A, Starzec W, Zaucha JM. Aktualne rekomendacje dotyczące diagnostyki i leczenia potransplantacyjnych zespołów limfoproliferacyjnych. Hematologia. 2012; 3: 127–35.
  71. Trappe RU, Dierickx D, Zimmermann H, et al. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2017; 35(5): 536–543.
    CrossRefPubMed
  72. Zimmermann H, Koenecke C, Dreyling MH, et al. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia. 2022; 36(10): 2468–2478.
    CrossRefPubMed
  73. Trappe R, Oertel S, Leblond V, et al. German PTLD Study Group, European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012; 13(2): 196–206.
    CrossRefPubMed
  74. Major A, Kamdar M. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. Curr Treat Options Oncol. 2018; 19(7): 33.
    CrossRefPubMed
  75. Dharnidharka VR, Martz KL, Stablein DM, et al. Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants. Am J Transplant. 2011; 11(4): 751–758.
    CrossRefPubMed
  76. Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013; 31(10): 1302–1309.
    CrossRefPubMed
  77. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005; 37(2): 954–955.
    CrossRefPubMed
  78. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010; 28(6): 1038–1046.
    CrossRefPubMed
  79. Styczynski J, van der Velden W, Fox CP, et al. Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7): 803–811.
    CrossRefPubMed
  80. Dierickx D, Habermann TM. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018; 378(6): 549–562.
    CrossRefPubMed
  81. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007; 109(6): 2571–2578.
    CrossRefPubMed
  82. Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother. 2005; 49(9): 3724–3733.
    CrossRefPubMed
  83. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005; 5(12): 2894–2900.
    CrossRefPubMed
  84. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998; 66(12): 1604–1611.
    CrossRefPubMed
  85. Humar A, Hébert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation. 2006; 81(6): 856–861.
    CrossRefPubMed
  86. Opelz G, Daniel V, Naujokat C, et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol. 2007; 8(3): 212–218.
    CrossRefPubMed
  87. AlDabbagh MA, Gitman MR, Kumar D, et al. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. Am J Transplant. 2017; 17(3): 770–781.
    CrossRefPubMed
  88. McIver Z, Stephens N, Grim A, et al. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. Biol Blood Marrow Transplant. 2010; 16(11): 1549–1556.
    CrossRefPubMed
  89. Petropoulou AD, Porcher R, Peffault de Latour R, et al. Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2012; 94(8): 879–883.
    CrossRefPubMed
  90. Dominietto A, Tedone E, Soracco M, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 2012; 47(1): 101–106.
    CrossRefPubMed
  91. van Esser JWJ, Niesters HGM, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002; 99(12): 4364–4369.
    CrossRefPubMed
  92. Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol. 2011; 155(3): 377–385.
    CrossRefPubMed
  93. Shah N, Eyre TA, Tucker D, et al. Haemato-Oncology Task Force of the British Society for Haematology and the British Transplantation Society. Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline. Br J Haematol. 2021; 193(4): 727–740.
    CrossRefPubMed
  94. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001; 71(8): 1076–1088.
    CrossRefPubMed
  95. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). Am J Transplant. 2011; 11(2): 336–347.
    CrossRefPubMed
  96. Rabot N, Büchler M, Foucher Y, et al. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Transpl Int. 2014; 27(9): 956–965.
    CrossRefPubMed
  97. Parker A, Bowles K, Bradley JA, et al. Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010; 149(5): 675–692.
    CrossRefPubMed
  98. Allen UD, Preiksaitis JK. AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9): e13652.
    CrossRefPubMed
  99. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation. 2002; 74(8): 1095–1102.
    CrossRefPubMed
  100. Parker A, Bowles K, Bradley JA, et al. Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010; 149(5): 675–692.
    CrossRefPubMed
  101. Rossignol J, Terriou L, Robu D, et al. Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab. Am J Transplant. 2015; 15(7): 1976–1981.
    CrossRefPubMed
  102. González-Barca E, Capote FJ, Gómez-Codina J, et al. GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas), GEL/TAMO (Grupo Español de Linfomas), GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear), GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas). Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007; 92(11): 1489–1494.
    CrossRefPubMed
  103. González-Barca E, Capote FJ, Gómez-Codina J, et al. GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas). Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. Ann Hematol. 2021; 100(4): 1023–1029.
    CrossRefPubMed
  104. Trappe R, Oertel S, Leblond V, et al. German PTLD Study Group, European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012; 13(2): 196–206.
    CrossRefPubMed
  105. Jain MD, Lam R, Liu Z, et al. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. Br J Haematol. 2020; 189(1): 97–105.
    CrossRefPubMed
  106. Sanz J, Storek J, Socié G, et al. Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study. Blood. 2021; 138(Supplement 1): 1454–1454.
    CrossRef
  107. Dharnidharka V, Thirumalai D, Jaeger U, et al. Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV +) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study. Blood. 2021; 138(Supplement 1): 2528–2528.
    CrossRef
  108. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012; 119(11): 2644–2656.
    CrossRefPubMed
  109. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007; 110(4): 1123–1131.
    CrossRefPubMed
  110. Kazi S, Mathur A, Wilkie G, et al. Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease. Haematologica. 2019; 104(8): e356–e359.
    CrossRefPubMed
  111. Prockop S, Gamelin L, Dinavahi R, et al. Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant. Blood. 2021; 138(Supplement 1): 887–887.
    CrossRef
  112. Rosenberg AS, Klein AK, Ruthazer R, et al. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. Am J Hematol. 2016; 91(6): 560–565.
    CrossRefPubMed
  113. Hong J, Johnson WT, Kartan S, et al. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Curr Oncol. 2021; 28(6): 5067–5072.
    CrossRefPubMed
  114. Zhou K, Gong D, Han Y, et al. Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review. Ann Hematol. 2024; 103(7): 2207–2213.
    CrossRefPubMed
  115. Portuguese AJ, Tykodi SS, Blosser CD, et al. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. J Natl Compr Canc Netw. 2022; 20(4): 406–416.e11.
    CrossRefPubMed
  116. Trappe RU, Choquet S, Reinke P, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab. Transplantation. 2007; 84(12): 1708–1712.
    CrossRefPubMed
  117. Oertel SH, Papp-Váry M, Anagnostopoulos I, et al. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol. 2003; 123(5): 830–835.
    CrossRefPubMed
  118. Esparza S, Muluneh B, Galeotti J, et al. Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia. Br J Haematol. 2020; 188(1): 173–177.
    CrossRefPubMed
  119. Keam SJ. Tabelecleucel: First Approval. Mol Diagn Ther. 2023; 27(3): 425–431.
    CrossRefPubMed
  120. Styczynski J, Sadlok J, Styczynski T, et al. Management of Resistant Post-transplant Lymphoproliferative Disorder: CAR-T Is a New Option. Anticancer Res. 2022; 42(11): 5181–5186.
    CrossRefPubMed
  121. Eyre TA, Caillard S, Finel H, et al. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2021; 56(9): 2118–2124.
    CrossRefPubMed
  122. Portuguese AJ, Gauthier J, Tykodi SS, et al. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. Bone Marrow Transplant. 2023; 58(4): 353–359.
    CrossRefPubMed
  123. McKenna M, Epperla N, Ghobadi A, et al. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. Br J Haematol. 2023; 202(2): 248–255.
    CrossRefPubMed
  124. Zimmermann H, Trappe RU. EBV and posttransplantation lymphoproliferative disease: what to do? Hematology Am Soc Hematol Educ Program. 2013; 2013: 95–102.
    CrossRefPubMed
  125. Zimmermann H, Reinke P, Neuhaus R, et al. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. Cancer. 2012; 118(19): 4715–4724.
    CrossRefPubMed
  126. Ferreiro JF, Morscio J, Dierickx D, et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. Haematologica. 2015; 100(7): e275–e279.
    CrossRefPubMed
  127. Mahale P, Shiels MS, Lynch CF, et al. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant. 2018; 18(2): 453–461.
    CrossRefPubMed
  128. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011; 96(7): 1067–1071.
    CrossRefPubMed
  129. Grześk E, Kołtan S, Dąbrowska A, et al. Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection. Front Immunol. 2022; 13: 915986.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note